Researchers are studying two medicines to see which works better for women with overactive bladder (OAB). OAB causes sudden urges to urinate, frequent bathroom trips, and sometimes leakage.
Women who join the study will be randomly placed into one of two groups:
One group will take tadalafil (5 mg), a medicine taken once a day.
The other group will take solifenacin (5 mg), a common treatment for OAB, also taken once a day.
The study will last 12 weeks. Participants will keep a bladder diary, answer short questionnaires, and have simple urine flow and bladder tests at several visits.
The main goal is to find out which medicine lowers OAB symptoms more, such as urgency and frequent urination. Researchers will also look at quality of life, bladder function, and side effects.
Women aged 18 to 75 years with OAB symptoms for at least 3 months may be able to take part.
OAB symptoms persisting for ≥3 months
OAB Symptom Score (OABSS) > 5 and urgency sub-score of OABSS ≥ 2
Ability and willingness to provide informed consent.
Active urinary tract infection.
Stress urinary incontinence (SUI) as primary diagnosis, or mixed urinary incontinence with predominant SUI
Pelvic organ prolapse stage ≥II according to POP-Q system.
History of pelvic radiation.
Mansoura University
Lead sponsor
Cairo University
Collaborator
Ain Shams University
Collaborator
Alexandria University
Collaborator
Zagazig University
Collaborator
Tanta University
Collaborator
Menoufia University
Collaborator
Assiut University
Collaborator
Sohag University
Collaborator
South Valley University
Collaborator
Beni-Suef University
Collaborator
Minia University
Collaborator
Aswan University
Collaborator